<SEC-DOCUMENT>0001062993-16-012807.txt : 20161222
<SEC-HEADER>0001062993-16-012807.hdr.sgml : 20161222
<ACCEPTANCE-DATETIME>20161222172038
ACCESSION NUMBER:		0001062993-16-012807
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20161222
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161222
DATE AS OF CHANGE:		20161222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		162067443

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR><B>Washington, D.C.
20549 </B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B>December 22,
2016 </B></P>
<P align=center><U><B><FONT size=5>LEXARIA BIOSCIENCE CORP.
</FONT></B><BR></U>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
    <TD align=center width="33%"><B><U>20-2000871</U> </B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>156 Valleyview Road, Kelowna, BC Canada </B></U></TD>
    <TD align=center width="50%"><U><B>V1X 3M4 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424 </U></B></P>
<P align=center><B><U>N/A </U></B><BR>(Former name or former address, if changed
since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp;&nbsp;]&nbsp;Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
<BR>[&nbsp;&nbsp;&nbsp;]&nbsp;Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR
240.14a-12)|<BR>[&nbsp;&nbsp;&nbsp;]&nbsp;Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))<BR>[&nbsp;&nbsp;&nbsp;]&nbsp;Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P align=justify><B>Item 1.01 Entry into a Material Definitive Agreement
</B></P>
<P align=justify>On December 22, 2016, Lexaria Bioscience Corp. (&#147;Lexaria&#148;)
announced that it has extended the services of Frontier Merchant Capital Group
(&#147;Frontier&#148;) with a head office in Toronto, Canada, for a period of three
months. Lexaria will pay CDN $25,000 + GST. The initial engagement of Frontier&#146;s
services was previously announced in Lexaria&#146;s news release dated June 6, 2016.
</P>
<P align=justify>Frontier will assist Lexaria by increasing market awareness
utilizing a number of financial market communication initiatives including media
outreach, facilitating in-person introduction for Lexaria with institutional and
retail brokers and investors in cities across Canada and the US, and more. </P>
<P align=justify><B>Item 7.01 Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing that Lexaria has extended
the services of Frontier Merchant Capital Group is filed as exhibit 99.1 to this
current report and is hereby incorporated by reference. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify><B>Item 9.01 Financial Statements and Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee ><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="95%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated December 22, 2016 </a></TD>
  </TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify><U><I>/s/ Chris Bunka </I><BR></U><B>Chris Bunka </B><BR>CEO,
Principal Executive Officer </P>
<P align=justify>Date: December 22, 2016 </P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">

<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Extends Investor Relations Agreement </B></P>
<P align=justify>Kelowna, BC / December 22, 2016 / Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148;) announces it has extended the services of
Frontier Merchant Capital Group (&#147;Frontier&#148;) with a head office in Toronto,
Canada, for a period of three months. Lexaria will pay CDN $25,000 + GST.</P>
<P align=justify>Frontier will assist the Company by increasing market awareness
utilizing a number of financial market communication initiatives including media
outreach, facilitating in-person introduction for the Company with institutional
and retail brokers and investors in cities across Canada and the US, and more.
</P>
<P align=justify>Lexaria&#146;s unique patented technology allows for more efficient
and effective absorption of certain molecules such as cannabinoids, while
simultaneously masking and at times even eliminating inherent strong flavours
and/or odors typical of those molecules. Lexaria&#146;s technology is extremely cost
effective to implement and applicable to the widest imaginable spectrum of
foods. </P>
<P align=justify>About Lexaria <BR>Lexaria Bioscience Corp. is a food sciences
company focused on the delivery of active compounds that can behave as
superfoods through its proprietary infusion technologies. Lexaria&#146;s technology
enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other
molecules than is possible without lipophilic enhancement technology. This can
allow for lower overall dosing requirements and/or higher effectiveness in
active molecule delivery. Lexaria hopes to reduce other common but less healthy
ingestion methods such as smoking as it embraces the benefits of public health.
<U>www.lexariaenergy.com</U> </P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>
  Lexaria Bioscience
Corp.<BR>Chris Bunka<BR>Chairman &amp; CEO<BR>(250) 765-6424 <BR></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_4></A>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>
  This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Access to capital, or lack thereof, is a major
risk and there is no assurance that the Company will be able to raise required
working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition, the patent application and approval process and other
factors which may be identified from time to time in the Company's public
announcements and filings. There is no assurance that the recent license
agreement, hemp oil sector, or alternative health businesses will provide any
benefit to Lexaria, or that the Company will experience any growth through
participation in these sectors or as a result of the license agreement. There is
no assurance that existing capital is sufficient for the Company's needs or that
it will be able to raise additional capital. There is no assurance that the
Company will receive all or any part of the $122,000 to $1,064,000 in
payments contemplated under the recently announced definitive license agreement.
There is no assurance that Lexaria will successfully complete any other
contemplated or existing technology license agreements, nor that Lexaria&#146;s
technology will deliver any improvement in taste or bioavailability with any
reliability nor across any product category. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever, nor that any patent application in the USA or any
other nation or under any treaty will result in the award of an actual patent;
nor that an award of any actual patent will protect against challenges from
unknown third parties. There is no assurance that any of Lexaria&#146;s postulated
uses, benefits, or advantages for the patent-pending technology will in fact be
realized in any manner or in any part. No statement herein has been evaluated by
the Food and Drug Administration (FDA). ViPova<SUP>TM</SUP> products are not
intended to diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>

<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
